2 Efficacy of HCV Protease Inhibitors in Co-Infected Patients Telaprevir + PegIFN/rUndetectable HCV RNA at week 1286% TP/r vs 33% placeboUndetectable HCV RNA at week 2474% TP/4 vs 55% placeboBoceprevir+ PegIFN/rUndetectable HCV RNA at week 1259.4% BOC+ P/r vs. 23.5% P/rUndetectable HCV RNA at week 2473.4% BOC+ P/r vs. 32.4% P/rDieterich D et al. Telaprevir in Combination with Pegylated Interferon--2a+RBV in HCV/HIV-co-infected Patients: A 24-Week Treatment Interim Analysis. CROI 2012 Paper #46Sulkowski M et al. Boceprevir + Pegylated Interferon + Ribavirin for the Treatment ofHCV/HIV-co-infected Patients: End of Treatment (Week-48) Interim Results. CROI 2012 Paper #47
3 Drug-Drug Interactions with Boceprevir (BOC) TenofovirEfavirenzRitonavirDrug Effect on BOCNoneslight reduction in AUC(0-8h) and Cmax (19% and 8%, respectively)44% decrease in Cmindecreased AUCt by 19%BOC Effect on DrugNo notable effect on AUC or renal clearance, but increased Cmax by 32%.slightly increased AUC(0-24h) & Cmax (20% & 11%, respectively)Kasserra C. et al. Clinical Pharmacology of BOC: Metabolism, Excretion, andDrug-Drug Interactions . CROI 2011 Paper #118
4 IL-28B Genotype and Treatment Response to PegIFN-RBV Rivero-Juarez A. et al. IL28B and the LDLr Have a Synergistic Effect on HCV Early Viral Kinetics duringthe First Weeks of Treatment with Pegylated Interferon + Ribavirin in HIV/HCV-co-infected Patients.CROI 2012 Paper #765
5 Predictors of Non-Response to Therapy with PegIFN-RBV Prometheus AUROCSensitivityPrometheus IndexSpecificityAvailable at:iTunes App StoreAndroid MarketMedrano J. et al. Baseline Prediction of Response to Pegylated Interferon + Ribavirin in ChronicHCV Using the Prometheus Score. CROI 2012 Paper #761
6 IL28B Genotype and HCV Viral Load Predictive values for SVR in patients infected with HCV genotype 1 (n=79).PPVNPVSensitivitySpecificityrs TT (n=53)45.2%80.7%82.7%42.0%Total nuclear-STAT1 (<5%) (n=30)50.0%71.4%51.7%70.0%rs TT or total nuclear-STAT1 (<5%) (n=61)42.6%83.3%89.6%30.0%rs TT and total nuclear-STAT1 (<5%) (n=22)59.0%71.9%44.8%82.0%Nuclear-STAT1, STAT1-nuclear translocation; PPV, positive predictive value; NPV, negative predictive value.Miyamura T, et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphismspredict treatment outcomes in hepatitis C virus genotype 1-infected patients.PLoS One. 2011;6(12):e Epub 2011 Dec 12.
7 Electronic Tools for Assessing Drug-Drug Interactions in HIV Infected Patients Online drug interaction chartsHIV iChartiPhone & Android appavailable on iTunes and theAndroid MarketiPhone Screenshot from iTunes Store
8 Incidence of HCV in the Swiss HIV Cohort Study, by Transmission Group Wandeler G.. et al. HCV Incidence in the SHCS: A Changing Epidemic . CROI 2012 Paper #743
9 2011 Treatment Guidelines AIDS 2011 Feb 20;25(4):399-409. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference.European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel.
10 The Role of Ribavirin in Treating HCV in Co-infected MSM In group 2,Sustained virological response (SVR) rates were significantly higher for peg-IFN+RBV (31 of 33) peg-IFN mono-therapy (6 of 10) (94% vs 60%, respectively; p = 0.02).SVR was significantly associated with Peg-IFN+RBV combination therapy (p = 0.037) and rapid virological response (p ≤0.0001)In group 1SVR was only significantly associated with rapid virological response (p ≤0.0001)HCV GenotypeGT1GT2GT3GT4Percent infected68%4.6%10.6%16.9%Boesecke C. et al. Ribavirin Is Needed in Addition to Pegylated Interferon for OptimalTreatment Responses in the Treatment of Acute HCV Genotype 2 and 3 Infection IHIV-co-infected Individuals . CROI 2012 Paper #50
11 Repeated Co-Infection With HCV in HIV Positive MSM Outcome of acute HCV according to episode number, pending patients on treatmentIngiliz P. et al. Prior HCV Infection Does Not Protect from Sexually Transmitted HCVReinfection in HIV+ MSM. CROI 2012 Paper #752